CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.27B, above the global median of $1.18B
- FinancialsAltman Z-Score 6.69: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
1.27BUSDvs all stocks (USD)
Revenue (TTM)
47.53MEURvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.33xvs all stocks
52-Week Change
5.82%vs all stocks
Market Capitalization
1.27BUSDvs all stocks (USD)
Enterprise Value
872.28MUSDvs all stocks (USD)
Forward P/E
-4.05xvs Biotechnology peers
Price to Sales (TTM)
30.55xvs Biotechnology peers
Price to Book (MRQ)
2.48xvs Biotechnology peers
Enterprise to Revenue
18.35xvs Biotechnology peers
Enterprise to EBITDA
-3.51xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-734.95%vs Biotechnology peers
Return on Assets (TTM)
-26.92%vs Biotechnology peers
Return on Equity (TTM)
-47.80%vs Biotechnology peers
Revenue (TTM)
47.53MEURvs all stocks (USD)
Revenue per Share (TTM)
0.3220EURUpdated Sep 27, 2026Quarterly Revenue Growth
93.00%vs Biotechnology peers
Gross Profit (TTM)
-201.40MEURvs all stocks (USD)
EBITDA (TTM)
-248.49MEURvs all stocks (USD)
Net Income (TTM)
-235.41MEURvs all stocks (USD)
Quarterly Earnings Growth (YoY)
93.03%vs Biotechnology peers
Operating Cash Flow (TTM)
-234.63MEURvs all stocks (USD)
Levered Free Cash Flow (TTM)
-144.22MEURvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
48.27MEURFY2025 · Dec 31, 2025Operating Income
-182.02MEUR-207.67M · vs all stocks (USD)
Pre-tax Income
-198.44MEURFY2025 · Dec 31, 2025Income Tax Expense
-1.99MEURFY2025 · Dec 31, 2025Net Income
-196.45MEURFY2025 · Dec 31, 2025EBIT
-197.49MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
-152.44MEURFY2025 · Dec 31, 2025Research & Development
183.83MEURFY2025 · Dec 31, 2025Selling, General & Administrative
51.18MEURFY2025 · Dec 31, 2025Other Operating Expenses
-4.73MEURFY2025 · Dec 31, 2025Non-operating Interest Income
17.18MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
946.00KEURFY2025 · Dec 31, 2025Net Income from Continuing Operations
-196.45MEURFY2025 · Dec 31, 2025Operating Cash Flow
-231.22MEURFY2025 · Dec 31, 2025Free Cash Flow
-237.78MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
345.92MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-196.45MEURFY2025 · Dec 31, 2025Depreciation & Amortization
12.40MEURFY2025 · Dec 31, 2025Deferred Taxes (CF)
-1.99MEURFY2025 · Dec 31, 2025Stock-based Compensation
15.02MEURFY2025 · Dec 31, 2025Other Non-cash Items
-16.23MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-242.00KEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-43.72MEURFY2025 · Dec 31, 2025Capital Expenditures
-6.56MEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-247.00KEURFY2025 · Dec 31, 2025Purchase of Investments
-338.27MEURFY2025 · Dec 31, 2025Sale of Investments
549.86MEURFY2025 · Dec 31, 2025Net Investing Cash Flow
205.03MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-2.96MEURFY2025 · Dec 31, 2025Other Financing Charges
-7.00MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
97.35MEURFY2025 · Dec 31, 2025Shares Outstanding
136.67MSharesUpdated Sep 27, 2026Float Shares
70.12MSharesUpdated Sep 27, 2026Shares Short
4.44MSharesUpdated Sep 27, 2026Short Ratio
6.71daysvs all stocks
Short % of Shares Outstanding
4.04%vs all stocks
% Held by Insiders
15.78%vs all stocks
% Held by Institutions
66.80%vs all stocks
Total Cash (MRQ)
448.30MEURvs all stocks (USD)
Total Cash per Share (MRQ)
2.88EURUpdated Sep 27, 2026Total Debt (MRQ)
16.65MEURvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0365xvs Biotechnology peers
Current Ratio (MRQ)
7.54xvs Biotechnology peers
Book Value per Share (MRQ)
3.37EURUpdated Sep 27, 2026Total Assets
562.34MEUR641.59M · vs all stocks (USD)
Total Current Assets
504.01MEURFY2025 · Dec 31, 2025Total Liabilities
78.24MEURFY2025 · Dec 31, 2025Total Non-current Assets
58.33MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
35.23MEURFY2025 · Dec 31, 2025Total Current Liabilities
43.01MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
345.92MEURFY2025 · Dec 31, 2025Other Short-term Investments
123.42MEURFY2025 · Dec 31, 2025Accounts Receivable
6.10MEURFY2025 · Dec 31, 2025Accounts Payable
340.00KEURFY2025 · Dec 31, 2025Short-term Debt
2.76MEURFY2025 · Dec 31, 2025Deferred Revenue
15.82MEURFY2025 · Dec 31, 2025Other Current Liabilities
1.55MEURFY2025 · Dec 31, 2025Long-term Debt
12.88MEURFY2025 · Dec 31, 2025Common Stock (Book)
1.34MEURFY2025 · Dec 31, 2025Retained Earnings
-785.99MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
484.10MEUR552.32M · vs all stocks (USD)
52-Week Low
7.73USDUpdated Sep 27, 202652-Week High
12.41USDUpdated Sep 27, 202652-Week Change
5.82%vs all stocks
Beta
1.33xvs all stocks
50-Day MA
9.13USDUpdated Sep 27, 2026200-Day MA
9.89USDUpdated Sep 27, 2026Avg 10-Day Volume
657.67KSharesUpdated Sep 27, 2026Avg 30-Day Volume
671.09KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-1.86EURUpdated Sep 27, 2026Other Income / Expense
-32.65MEURFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.93Receivables vs revenue divergence: 3.33
Financial Health
Altman Z-Score 6.69: safe zoneNotable
Altman Z-Score: 6.69
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.27B, above the global median of $1.18BNotable
Market cap (USD): 1,274,123,894Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Jiangsu Yahong Meditech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Damora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Akums Drugs & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bicara Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Yizhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xianju Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Changzhou Qianhong Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Hisun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Integra LifeSciences Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sinocare Inc.
Tier 1ProductionApproval-Gated PipelineRule